Psychiatric Medications — A Clinical Guide to the Landscape

Capstone to the pharmacology series — how the drug classes relate, the cross-cutting principles that govern them all, and a prescribing guide by presentation

What This Series Is

This pharmacology series examines the drugs of psychiatry in ten documents, each written to a consistent standard: an accurate account of what the class is, how it works (at the level of receptors and likely mechanism), what it genuinely does for patients, and what its real burdens and controversies are — with the criticisms and limitations treated as load-bearing content rather than disclaimers, and with the recurring honesty that what patients actually receive is shaped as much by safety, tolerability, marketing, and clinician familiarity as by efficacy.

The ten documents: serotonergic agents (SSRIs, SNRIs, the multimodal antidepressants, azapirones); glutamatergic and rapid-acting agents (ketamine, the neurosteroids); mood stabilizers (lithium, the anticonvulsants, the antipsychotics-as-stabilizers); sympatholytics (alpha-2 agonists, beta-blockers, prazosin); stimulants and ADHD medications; antipsychotics; GABAergic agents (benzodiazepines, Z-drugs, barbiturates, gabapentinoids); psychedelics and consciousness-altering agents; the atypical and non-classical agents (bupropion, mirtazapine, the repurposed non-psychiatric drugs); and the first-generation antidepressants (TCAs and MAOIs).

This capstone does three things: maps the classes, distills the cross-cutting principles the whole series supports, and offers a prescribing guide organized by clinical presentation. It is a companion to the parallel psychotherapy series and its capstone, and the two should be read together — because the deepest practical conclusion of both is that drugs and psychotherapy are colleagues, not rivals.

The Map: Ten Classes by What They Target

Psychiatric drugs can be organized by the neurochemical system they act on and the clinical problem they address:

The monoaminergic antidepressants — serotonergic (SSRIs, SNRIs, multimodal), the atypicals (bupropion's dopamine-norepinephrine action, mirtazapine's receptor antagonism), and the first-generation TCAs and MAOIs — all raise monoamine transmission by various routes (reuptake blockade, receptor antagonism, enzyme inhibition), share a delayed onset, and converge downstream on neuroplastic change. Their efficacy is modest-but-real, stronger for anxiety disorders than the depression debate implies, and — crucially — the progression from first-generation to SSRIs was advance in safety and tolerability, not efficacy.

The rapid-acting agents — ketamine/esketamine (glutamatergic) and the neurosteroids (GABAergic) — break the monoaminergic delayed-onset paradigm, working in hours by inducing plasticity through a different door, and represent the most important mechanistic shift in antidepressant pharmacology in a generation.

The mood stabilizers — lithium (the irreplaceable prototype), the anticonvulsants (valproate, lamotrigine, carbamazepine), and the antipsychotics-as-stabilizers — manage the bipolar spectrum unevenly, with no unified mechanism, and a structural weakness against the depressive pole that dominates the illness burden.

The antipsychotics — typical and atypical D2 antagonists and partial agonists — dampen the aberrant salience of psychosis well, leave its negative and cognitive symptoms largely untouched, and carry serious movement and metabolic burdens; clozapine stands uniquely effective and uniquely underused.

The catecholaminergic stimulants — methylphenidate, the amphetamines, and the non-stimulants — optimize prefrontal catecholamine signaling in ADHD with effect sizes among the largest in psychiatry, raising distinct abuse, cardiovascular, and diagnostic-boundary concerns.

The inhibitory and dampening agents — the GABAergics (benzodiazepines and relatives), which enhance inhibition fast and effectively at the cost of intrinsic dependence, and the sympatholytics (alpha-2 agonists, beta-blockers, prazosin), which dampen the noradrenergic/autonomic output of arousal symptomatically and cleanly.

The consciousness-altering agents — psychedelics (5-HT2A), entactogens (MDMA), dissociatives (ketamine), and atypicals (ibogaine) — induce dramatic plasticity and altered states, promising for serious and treatment-resistant conditions, and freighted with methodological, safety, and hype problems.

The non-classical and repurposed agents — anti-inflammatories (including TNF-alpha inhibitors), antibiotics (minocycline, D-cycloserine), metabolic drugs (GLP-1 agonists, metformin), and hormones (thyroid, neurosteroids) — work outside the neurotransmitter model, often in biologically-defined subgroups, and point toward a stratified, systems-level future for the field.

The Comparison at a Glance

Class	Core mechanism	Best-evidenced uses	Reach for it when	Chief caution
SSRIs/SNRIs	Serotonin (±NE) reuptake blockade → plasticity	Depression, anxiety disorders, OCD, PTSD	First-line for most depression/anxiety	Modest effect in mild depression; sexual dysfunction; withdrawal
Atypical antidepressants (bupropion, mirtazapine, trazodone)	NDRI / receptor antagonism	Depression with specific profiles	Sexual SE, weight, sedation, insomnia, smoking matter	Bupropion: anxiety/seizure; mirtazapine: sedation/weight
TCAs	NE/5-HT reuptake + broad receptor blockade	Severe/melancholic & resistant depression, neuropathic pain, OCD (clomipramine)	First-line agents fail; pain comorbidity	Lethal in overdose; anticholinergic; cardiac
MAOIs	Monoamine oxidase inhibition (triple monoamine)	Atypical & treatment-resistant depression	Atypical features; multiple failures	Tyramine/serotonergic interactions; dietary restriction
Ketamine/neurosteroids	NMDA antagonism / GABA-A modulation → rapid plasticity	TRD, acute suicidality (ketamine); postpartum depression (neurosteroids)	Need for speed; treatment resistance; postpartum	Transient effect; ketamine abuse/bladder; cost/access
Lithium	GSK-3β/inositol/neuroprotection	Bipolar maintenance; uniquely antisuicidal	Bipolar maintenance (underused)	Narrow window; renal/thyroid; monitoring burden
Anticonvulsant stabilizers	Varied (Na channels, GABA, glutamate)	Mania (valproate); bipolar depression (lamotrigine)	Phase-specific bipolar treatment	Valproate teratogenicity; lamotrigine rash
Antipsychotics	D2 antagonism/partial agonism (±5-HT2A)	Psychosis; bipolar; adjunct depression	Positive symptoms, mania, acute agitation	EPS/tardive dyskinesia; metabolic syndrome; overuse
Clozapine	Promiscuous; loose D2	Treatment-resistant schizophrenia (uniquely); antisuicidal	TRS after two failures	Agranulocytosis; myocarditis; underused
Stimulants	DA/NE reuptake block / release	ADHD (large effect); narcolepsy	ADHD, first-line	Abuse/diversion; cardiovascular; growth; overdiagnosis
Benzodiazepines	GABA-A positive modulation	Withdrawal, status epilepticus, catatonia; acute anxiety	Acute/specific inhibitory problems	Tolerance/dependence/withdrawal; opioid interaction
Sympatholytics	α2 agonism / β-block / α1-block	ADHD, performance anxiety, akathisia, PTSD nightmares	Autonomic/somatic arousal symptoms	Hypotension; clonidine rebound; symptomatic only
Psychedelics	5-HT2A agonism (mostly) → plasticity	(Investigational) depression, PTSD, end-of-life distress, addiction	Investigational/regulated settings only	Psychosis/mania contraindication; blinding crisis; physical risks
Repurposed/non-classical	Immune, metabolic, endocrine, glutamatergic-learning	Subgroup-specific (inflamed, deficient)	Biomarker-defined subgroups; augmentation	Mostly promising-not-proven; subgroup-restricted

Seven Cross-Cutting Principles

The whole series supports a set of conclusions that transcend any single class:

1. The plasticity convergence. The deepest theme: the antidepressants (slowly), ketamine and the psychedelics (rapidly), and lithium (via neuroprotection) appear to converge on a common downstream endpoint — BDNF-mediated synaptic plasticity and the reopening of networks to experience-dependent change — rather than on correcting a neurotransmitter "imbalance." The center of gravity in understanding psychiatric drug action has shifted from "which chemical is wrong" to "how do we induce a plastic, reorganization-permitting brain state." This reframing dissolves the old chemical-imbalance story (which was never seriously held by specialists and has empirically collapsed) and explains the delayed onset, the transdiagnostic profiles, and — critically — why combination with psychotherapy and a workable environment so reliably outperforms medication alone: the drug opens the window; what comes through it depends on the experience and the context.

2. Mechanism is poorly understood, and efficacy does not depend on the etiological theory. Across the series, the mechanisms are incompletely understood (lithium's after 75 years; clozapine's uniqueness; the SSRIs' delay; ketamine's metabolite debate), and — the crucial logical point — a drug's efficacy is independent of whether the disease is a deficiency of that drug's target. Aspirin treats headache though headache is not an aspirin deficiency; SSRIs treat depression though depression is not a serotonin deficiency. The collapse of the monoamine hypothesis as etiology changes how we should explain these drugs, not whether we should use them.

3. Newer usually meant safer, not more effective. The history is one of advancing deliverability — overdose safety, tolerability, ease of prescribing — far more than antidepressant or antipsychotic power. The TCAs and MAOIs are equal or superior antidepressants demoted on safety; the atypical antipsychotics improved tolerability (EPS) more than efficacy; the Z-drugs and gabapentinoids were "safer benzodiazepine alternatives" that carried their own versions of the same problems. Assuming newer means more effective misreads the field.

4. The most effective drugs are often the most underused — for non-efficacy reasons. Lithium (best bipolar maintenance, uniquely antisuicidal), clozapine (only agent for treatment-resistant schizophrenia, antisuicidal), and the MAOIs (best for atypical depression) are all underused — neglected because they are old, unprofitable, demanding to monitor, or interaction-laden, and because the clinical expertise to use them has atrophied. What patients receive is shaped by safety, marketing, monitoring burden, and familiarity as much as by efficacy — and the most effective option is frequently not the one prescribed.

5. Effect sizes are moderate, remission is the minority, and the right response to non-response is sequencing and combination — not brand loyalty. Honest effect sizes across the series are moderate, absolute remission rates humbling (roughly half respond to any single adequate course; STAR*D's durable remission was a minority), and the rational response to the common case of inadequate response is systematic sequencing, augmentation, and combination — and, importantly, reaching for the underused effective options (lithium, clozapine, MAOIs, TCAs) rather than cycling through interchangeable first-line agents.

6. The mechanism that produces the benefit often produces the liability — and stratification is the future. Several classes show that benefit and harm are mechanistically inseparable (GABAergic potentiation → both anxiolysis and dependence; serotonergic dampening → both relief and emotional blunting; D2 blockade → both antipsychotic effect and movement disorders). And the repurposed agents show that the drugs increasingly work in biologically-defined subgroups (the inflamed, the deficient) rather than unselected diagnostic populations — pointing toward a stratified, biomarker-guided psychiatry that matches the drug to the specific biology of the specific patient, the most important structural change coming to the field.

7. Read all efficacy claims with four standard discounts, and all drugs with honest consent. Researcher allegiance inflates; weak comparators (waitlists, de-fanged "supportive" controls, placebo) inflate; early small trials inflate (effects decline as literatures mature); and signature-ingredient stories outrun dismantling data (the serotonin imbalance, EMDR's eye movements, the psychedelic trip's necessity, ketamine's NMDA-vs-metabolite debate). None of this hollows the drugs; it makes honest informed consent — uncertain mechanism, modest-to-moderate benefit, real trade-offs, the need to plan discontinuation — both more truthful and better medicine than the certainty the field once projected.

The Prescribing Guide by Presentation

Where the evidence concentrates, by clinical situation. (This synthesizes the series; it is educational, not a protocol, and not a substitute for individualized clinical judgment.)

Major depression, mild. Drug-specific benefit is weakest here (the severity-dependence finding); psychotherapy, behavioral activation, and watchful waiting often appropriate first. If medication, an SSRI by default.

Major depression, moderate-to-severe. SSRI or SNRI first-line; combine with psychotherapy (combination outperforms either). Match the atypicals to profile: bupropion (sexual SE, weight, fatigue, smoking), mirtazapine (insomnia, poor appetite). For severe/melancholic, consider that TCAs may outperform SSRIs. Combination (medication + psychotherapy) is optimal for severe and recurrent illness.

Treatment-resistant depression. The underused-effective-options territory: switch class, augment (lithium — also antisuicidal; T3/thyroid; atypical antipsychotic; buspirone), and remember the genuinely underused effective agents — MAOIs (especially atypical features), TCAs, and, for the right patient, ketamine/esketamine (rapid, for treatment resistance and acute suicidality). Combination with psychotherapy throughout.

Depression with acute suicidality. Ketamine/esketamine for rapid anti-suicidal effect; lithium for its uniquely antisuicidal maintenance effect in mood disorders; clozapine if schizophrenia-spectrum. Means restriction and safety planning regardless; avoid lethal-in-overdose agents (TCAs) in at-risk patients.

Postpartum depression. Neurosteroids (zuranolone oral, brexanolone IV) for rapid mechanism-matched action; SSRIs (sertraline favored); IPT and CBT (psychotherapy series).

Recurrent depression — staying well. Maintenance antidepressant; maintenance IPT; MBCT (the supervised route to tapering medication) — see the psychotherapy series.

Anxiety disorders (GAD, panic, social anxiety). SSRIs/SNRIs first-line (robust here — stronger than the depression debate implies); buspirone for GAD and augmentation (non-addictive); benzodiazepines for acute/short-term use only (dependence with chronic use); beta-blockers for somatic performance anxiety; pregabalin for GAD; CBT first-line or combined (psychotherapy series).

OCD. SSRIs at high doses, long latency; clomipramine (uniquely effective TCA); combined with ERP (psychotherapy series). NAC as a low-risk adjunct.

PTSD. SSRIs (sertraline, paroxetine — modest); prazosin for trauma nightmares (selected patients); trauma-focused psychotherapy or EMDR first-line (psychotherapy series); MDMA-assisted therapy investigational (rejected 2024).

Bipolar disorder. Mania: antipsychotic ± lithium/valproate. Bipolar depression (the hard problem): quetiapine, lurasidone, cariprazine, lamotrigine, lithium, olanzapine-fluoxetine — not antidepressant monotherapy (switch risk). Maintenance: lithium first (and uniquely antisuicidal), lamotrigine for depression-predominant, by profile otherwise. Valproate contraindicated in women of childbearing potential.

Schizophrenia and psychosis. Antipsychotics first-line (lowest effective dose, metabolically-conscious choice); clozapine for treatment resistance (after two failures — and underused, consider earlier); long-acting injectables for adherence; the long-term dose/duration genuinely uncertain (individualize).

ADHD. Stimulants (methylphenidate, amphetamines) first-line and highly effective; non-stimulants (atomoxetine, alpha-2 agonists) when abuse/diversion is a concern or stimulants poorly tolerated; pair with behavioral/educational support.

Insomnia. CBT-I first-line (psychotherapy series), before hypnotics; if pharmacologic, prefer non-dependence-forming options (low-dose doxepin, trazodone, mirtazapine if depressed) over chronic benzodiazepines/Z-drugs.

Alcohol/sedative withdrawal, status epilepticus, catatonia. Benzodiazepines — first-line, sometimes life-saving, the indications where their mechanism is exactly right.

Addiction. Naltrexone, acamprosate (alcohol); buprenorphine/methadone/naltrexone (opioids); GLP-1 agonists (emerging, promising); ibogaine (investigational, cardiac-dangerous); psychedelics (investigational).

Serious medical illness / demoralization / end of life. Meaning-centered and existential psychotherapy (psychotherapy series); psilocybin investigational for end-of-life distress; treat comorbid depression conventionally.

The Integration That Both Series Point To

The single most important conclusion uniting this pharmacology series with its psychotherapy companion is that drugs and psychotherapy are colleagues, not rivals — and the plasticity reframing explains why. If psychiatric drugs work substantially by inducing a plastic, reorganization-permitting brain state (Principle 1), then what the newly malleable brain encounters — psychotherapy, behavioral change, a workable environment, "set and setting" — is not adjunctive but central to the outcome. This is why combination treatment reliably outperforms either alone for serious illness, why the rapid-acting and psychedelic agents are delivered embedded in psychotherapy, and why medication deployed as a fast, solitary, indefinite substitute for psychosocial intervention represents a misuse of the mechanism rather than a use of it. The drug opens the window; the therapy and the life fill it.

The corresponding caution, also uniting both series, is against the deployment failure: psychiatric treatments — drugs especially — are repeatedly reached for too fast, too alone, too indefinitely, and oversold, in systems poorly equipped to provide the surrounding care the mechanism requires. The disciplined alternative that both series converge on: match the treatment to the specific patient and condition; combine pharmacology with psychotherapy for serious illness; favor the genuinely effective but underused options (lithium, clozapine, the MAOIs and TCAs, and the psychotherapies) over reflexive first-line cycling; consent honestly about uncertain mechanisms, moderate benefits, and real trade-offs; reassess rather than continue by default; and hold, throughout, the recognition that these are useful, imperfect, incompletely-understood tools that help a great many people when used well — and harm or disappoint when used as the hype, the marketing, or the convenience of the system invites.

Using the Series

Each pharmacology document follows a consistent architecture — what the class is, the relevant neurochemistry, mechanism, the agents in detail, what they actually do, the problems, a theoretical synthesis, and a clinical bottom line — and cross-references the others, so they function as standalone references or a linked library. Together with the thirteen-document psychotherapy series and its capstone, they form a comprehensive, evidence-based, honestly-balanced account of how psychiatry actually treats the mind — pharmacologically and psychotherapeutically — and of the genuine uncertainties that remain in both.

The pharmacology series:

1. Serotonergic agents — SSRIs, SNRIs, multimodal antidepressants, azapirones; the plasticity reframing and the serotonin-hypothesis debate.
2. Glutamatergic and rapid-acting agents — ketamine, neurosteroids; the paradigm shift in antidepressant speed and theory.
3. Mood stabilizers — lithium, anticonvulsants, antipsychotics-as-stabilizers; the bipolar-depression gap.
4. Sympatholytics — alpha-2 agonists, beta-blockers, prazosin; treating the autonomic output of arousal.
5. Stimulants and ADHD medications — the inverted-U, large effects, and the diagnostic-boundary debates.
6. Antipsychotics — the salience hypothesis, clozapine, the long-term-outcome controversy.
7. GABAergic agents — benzodiazepines and relatives; the benefit-and-dependence tension.
8. Psychedelics — the consciousness-altering agents; plasticity, promise, and the methodological crisis.
9. Atypical and non-classical agents — bupropion, mirtazapine, and the repurposed non-psychiatric drugs; the stratified future.
10. TCAs and MAOIs — the first-generation antidepressants; superseded on safety, not efficacy.